Retatrutide

Retatrutide is an investigational once-weekly peptide developed by Eli Lilly that acts as a triple agonist of three receptors at once: GLP-1, GIP, and glucagon. It is currently in late-stage clinical research and has not yet received regulatory approval. It is one of the most-anticipated next-generation metabolic peptides because of the unusually large weight-loss numbers observed in its phase 2 trial.

Semaglutide pulls one lever. Tirzepatide pulls two. Retatrutide pulls three. The third lever — glucagon — is interesting because glucagon increases energy expenditure (the rate your body burns calories), not just appetite control. Combining all three is the leading bet from major pharmaceutical research on how to push weight-loss results beyond what GLP-1/GIP can do alone. Online, it is described as the 'big one to watch' in the GLP-1 era.

Retatrutide activates the GLP-1 receptor (satiety, insulin), the GIP receptor (insulin response, adipose function), and the glucagon receptor (hepatic glucose handling, lipolysis, thermogenesis). The glucagon component is what distinguishes it from dual agonists: instead of only reducing energy intake, it appears to also increase energy expenditure. Balancing glucagon activity is the challenge, since unopposed glucagon can raise blood sugar — but the GLP-1 component counters this in clinical observation.

• •Obesity and weight management (phase 3)
• •Type 2 diabetes
• •Non-alcoholic fatty liver disease (NAFLD/MASH)
• •Cardiovascular outcomes (investigational)
• •Energy expenditure and metabolic rate research
• •Combination metabolic therapy

Retatrutide is the most-anticipated next-generation GLP-1 peptide in online metabolic discussion. The phase 2 results — average weight losses substantially exceeding semaglutide and tirzepatide — drove intense attention. Conversations focus on whether the effect translates to phase 3, on side-effect profile (which appears broadly similar to other incretin therapies but with additional glucagon-related considerations), and on when it might become commercially available. It is heavily compared to mazdutide and survodutide, the other emerging triple/dual glucagon-containing compounds.

“The triple-threat metabolic peptide.”

Retatrutide is discussed as a standalone in most online conversation because its triple mechanism already covers what people would otherwise try to stack. In research speculation, people occasionally discuss it alongside amylin analogs like cagrilintide for additive satiety, but no established protocols exist.

Retatrutide is an investigational once-weekly triple agonist of the GLP-1, GIP, and glucagon receptors developed by Eli Lilly. Its phase 2 trial produced some of the largest non-surgical weight-loss results ever recorded, making it the most-anticipated next-generation metabolic peptide and the leading benchmark for the post-tirzepatide era.